Anteris Technologies Global Corp. (ASX: AVR)

Market Cap	339.63M
Revenue (ttm)	4.08M
Net Income (ttm)	-103.51M
Shares Out	35.94M
EPS (ttm)	-5.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,413
Average Volume	17,669
Open	9.76
Previous Close	9.45
Day's Range	9.30 - 9.82
52-Week Range	7.65 - 23.93
Beta	0.76
RSI	54.70
Earnings Date	Feb 7, 2025

About ASX: AVR

Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaf...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Employees: 138
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AVR

Financial Performance

In 2023, AVR's revenue was $4.11 million, a decrease of -10.43% compared to the previous year's $4.59 million. Losses were -$67.33 million, 51.9% more than in 2022.

Financial numbers in USD